Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
See Latest ArticlesDuloxetine in the treatment of irritable bowel syndrome: an open-label pilot study
Human Psychopharmacology: Clinical and Experimental, 07/01/09
Brennan BP et al. - Open-label study, duloxetine appeared to be effective for many features of IBS, but its adverse effects, most notably constipation, limited its use. Since our study excluded individuals with concurrent major depression, it appears that duloxetine may benefit IBS independently of its antidepressant effects. These encouraging but preliminary open-label findings support further investigation of duloxetine treatment in placebo-controlled trials of IBS.
Methods- Open-label 12-week trial of duloxetine 60 mg daily in 15 patients with IBS without concurrent major depressive disorder.
- The primary outcome measure was average abdominal pain.
- Secondary measures included IBS symptoms, Clinical Global Impression-Severity, Hamilton Anxiety Rating Scale, IBS Quality-of-Life Scale, and Sheehan Disability Scale.
- Analyzed changes using random regression and one-sample t-tests.
- Fourteen patients completed at least one post-baseline evaluation; eight completed the study.
- Duloxetine was associated with significant improvement (p < 0.05) in pain, severity of illness, quality of life, loose stool, work and family disability, and anxiety.
- However, duloxetine did not improve hard stool.
- Found no evidence of serious duloxetine toxicity, seven participants withdrew over the course of the study because of adverse drug events.
Related Articles
The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: Results from three clinical trials
Journal of Anxiety Disorders, 11/13/09
Relevance Score: 66%
Fibromyalgia: The diagnosis and pharmacologic treatment
European Journal of Pain, 11/12/09
Relevance Score: 64%
Milnacipran, a serotonin and norepinephrine reuptake inhibitor: a novel treatment for fibromyalgia
International Journal of Clinical Rheumatology, 10/19/09
Relevance Score: 64%
Review: differences in efficacy and acceptability exist for 12 new-generation antidepressants for major depression
Evidence-Based Medicine, 10/26/09
Relevance Score: 63%
Tinnitus in postherpetic neuralgia
The Journal of Headache and Pain, 10/26/09
Relevance Score: 62%
Today in Mood Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: An open-label study
World Journal of Biological Psychiatry, 12/03/09
Increased Cold-Pain Thresholds in Major Depression
The Journal of Pain, 12/03/09
Mindfulness-Based Attention as a Moderator of the Relationship Between Depressive Affect and Negative Cognitions
Cognitive Therapy and Research, 12/02/09
Today in Neuro/Psych Pharmacol...keeping you current
Receive free subspecialty "5-minute updates" via email
Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: An open-label study
World Journal of Biological Psychiatry, 12/03/09
Asenapine for schizophrenia and bipolar I disorder
Current Psychiatry, 12/03/09
Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial
Schizophrenia Research, 12/03/09
Today in Other Psychiatry...keeping you current
Receive free subspecialty "5-minute updates" via email
Asenapine for schizophrenia and bipolar I disorder
Current Psychiatry, 12/03/09
Specific and Generalized Neuropsychological Deficits: A Comparison of Patients With Various First-Episode Psychosis Presentations [research-article]
American Journal of Psychiatry, 12/03/09
Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial
Schizophrenia Research, 12/03/09
Sponsor
Article Search
Sponsor